Meridian Bioscience Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Meridian Bioscience Inc (VIVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Meridian Bioscience Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 302M vs 0M combined for tracked competitors (99.9% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-24.5% annualized vs trailing 12 months), vs accelerating (+90.0%) for its tracked peer group.
- Growth: Meridian Bioscience Inc generated -35.6% revenue growth year over year in Q2 2022, vs 38,337.7% for its tracked competitors combined.
- Profitability: Its -52.4% net margin compares with -10,647.0% for the peer group.
- Peer revenue share: Meridian Bioscience Inc accounted for 99.8% of combined revenue among its tracked peer group, down from 100.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.35M compares with $0.03M for the peer group (13.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VIVO Sales vs. its Competitors, Q2 2022
Meridian Bioscience Inc reported revenue contraction of 35.59 % year on year in Q2 2022, below its competitors' combined revenue growth of 38,337.66 %.
With a net margin of -52.41 %, Meridian Bioscience Inc achieved higher profitability than its competitors (-10,646.97 %).
Meridian Bioscience Inc generated 99.79 % of the combined sales of its peer group, down from 100.00 % a year earlier.
Meridian Bioscience Inc vs. its Competitors, Q2 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Meridian Bioscience Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Meridian Bioscience Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Meridian Bioscience Inc's competitor groups requires a Commercial License.
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -35.6% for Meridian Bioscience Inc. Meridian Bioscience Inc's share of combined industry revenue moved from 2.64% to 1.66%, a loss of 0.98 percentage points.
Meridian Bioscience Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Meridian Bioscience Inc | No | No | No | Yes |
| Competitors combined (1) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 50.00 % (4 of 8) | 50.00 % (4 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VIVO Stock Performance relative to its Competitors
VIVO Stock Performance relative to Similar Growth & Profitability Competitors
Publicly Traded Peers of Meridian Bioscience Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Meridian Bioscience Inc | 136.52 | 301.58 |
| Endonovo Therapeutics Inc | 0.14 | 0.26 |
| SUBTOTAL | 136.65 | 301.83 |
Sources: Meridian Bioscience Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Meridian Bioscience Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Meridian Bioscience Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Meridian Bioscience Inc | Diagnostics 69.18 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Meridian Bioscience Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Meridian Bioscience Inc | 137 | 354,799 | -3,179 |
| Endonovo Therapeutics Inc | 0 | 25,572 | -440,414 |
| PEERS TOTAL | 0 | 25,572 | -440,414 |
Meridian Bioscience Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 18 companies in Meridian Bioscience Inc's industry classification, broader than the peer set above. Market cap in millions of $.Meridian Bioscience Inc ranks #0 of 18 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 5,329, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Idexx Laboratories Inc | 41,147 | 71.65 % |
| 2 | Lantheus Holdings Inc | 6,749 | 11.75 % |
| 3 | Neogen Corporation | 3,010 | 5.24 % |
| 4 | Celldex Therapeutics inc | 2,387 | 4.16 % |
| 5 | Intellia Therapeutics Inc | 1,234 | 5.2% |
| 6 | Quidelortho Corp | 1,234 | 5.2% |
| 7 | Achieve Life Sciences Inc | 1,234 | 5.2% |
| 8 | Alpha Teknova Inc | 1,234 | 5.2% |
| 9 | Myriad Genetics Inc | 1,234 | 5.2% |
| 10 | Insight Molecular Diagnostics Inc | 1,234 | 5.2% |
| 0 | Meridian Bioscience Inc | 274 | 0.00 % |
Market cap and industry share for the rest of Meridian Bioscience Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-29.
Meridian Bioscience Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the In Vitro & In Vivo Diagnostic Substances industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (18 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 56.60 % | 37.70 % (avg) | +18.9 pp |
| Operating Margin | 1.99 % | industry median | +29.8 pp |
| EBITDA Margin | 7.51 % | -15.74 % (avg) | +23.3 pp |
| Capital Intensity (Capex / Revenue) | 3.17 % | 4.23 % (avg) | -1.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Meridian Bioscience Inc's Valuation vs Competitive Position
Valuation multiples vs the In Vitro & In Vivo Diagnostic Substances industry average (18 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 52.0x | - |
| EV / EBITDA | 4.7x | 16.5x | -11.8x |
| P/B | 0.4x | 4.6x | -4.2x |
| Return on Equity | -0.75 % | industry aggregate | -2.25 % |
| Return on Invested Capital | 0.79 % | 0.79 % (avg) | 0.00 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Meridian Bioscience Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 1.00 % | 0.90 % | 5.37 % | 3.16 % | -7.43 % | 51.89 % | 4.73 % | -3.75 % |
| Operating Margin | 29.37 % | 24.46 % | 17.14 % | 16.01 % | 13.98 % | 30.28 % | 25.10 % | 1.99 % |
| Return on Invested Capital | 17.17 % | 11.96 % | 8.88 % | 8.42 % | 5.80 % | 15.41 % | 10.76 % | 0.79 % |
| P/E | 113.0x | 119.9x | 28.7x | 29.4x | 20.8x | 58.7x | 27.5x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Meridian Bioscience Inc's Strategic Group Map
Every company in Meridian Bioscience Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Meridian Bioscience Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Meridian Bioscience Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 5,329 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.17 % vs industry average 4.23 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Meridian Bioscience Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Meridian Bioscience Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Meridian Bioscience Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Meridian Bioscience Inc falls in the Medium attractiveness / High strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Meridian Bioscience Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 29.8 points above the industry median.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-24.5% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Industry dominated by Idexx Laboratories Inc, holding 71.65 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Meridian Bioscience Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Meridian Bioscience Inc | 1.25 | 3.32 | 0.07 |
| Endonovo Therapeutics Inc | 0.00 | 0.00 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Meridian Bioscience Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Meridian Bioscience Inc | Q4 2022 | -35.6 % | - |
| Endonovo Therapeutics Inc | Q3 2023 | -86.1 % | - |
| PEERS TOTAL | -35.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Meridian Bioscience Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Meridian Bioscience Inc | Q4 2022 | -35.2 % | +55.4 % |
| Endonovo Therapeutics Inc | Q3 2023 | -79.5 % | - |
Meridian Bioscience Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Meridian Bioscience Inc | - | - | - |
| Endonovo Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Meridian Bioscience Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Meridian Bioscience Inc | - | 0.45 |
| Endonovo Therapeutics Inc | - | 0.53 |
| PEERS AVERAGE | - | 0.45 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.